Other grades of this product :
| 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile Basic information |
| 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile Chemical Properties |
| Melting point | 245℃ | | Boiling point | 634.1±65.0 °C(Predicted) | | density | 1.27 | | storage temp. | Refrigerator | | solubility | Acetone (Slightly), Chloroform (Slightly), DMSO (Slightly), Water (Very Slightly | | form | Solid | | pka | 4.56±0.10(Predicted) | | color | Yellow |
| 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile Usage And Synthesis |
| Description | In May 2011, the U.S. FDA approved rilpivirine in combination with other
antiretroviral agents for the treatment of human immunodeficiency virus
(HIV) 1 infection in treatment-naive adult patients.
Rilpivirine is a member of the nonnucleoside reverse transcriptase inhibitor (NNRTI) class of anti-HIV
agents. It is highly potent against a range of wild-type HIV strains
(EC50=0.07–1.0 nM),～10–20 timesmore potent than the NNRTI efavirenz
(Sustiva), and active against HIV strains resistant to other NNRTIs. The
discovery of rilpivirine was guided by molecular modeling and X-ray
crystallography of HIV-1 RT complexed with inhibitors. The synthesis
of rilpivirine is accomplished by an efficient 6-step route in which the key
step is coupling of 4-((4-chloropyrimidin-2-yl)amino)benzonitrile with (E)-3-(4-amino-3,5-dimethylphenyl)acrylonitrile. | | Chemical Properties | N/ABright Yellow Solid | | Originator | Janssen (Belgium) | | Uses | A novel non-nucleoside reverse transcriptase inhibitor. Rilpivirine seems to be well tolerated with less CNS disturbance than Efavirenz, and has non-teratogenic potential. An anti-HIV agent. | | Uses | A novel non-nucleoside reverse transcriptase inhibitor. Rilpivirine seems to be well tolerated with less CNS disturbance than Efavirenz, and has non-teratogenic potential. | | Definition | ChEBI: An aminopyrimidine that is pyrimidine-2,4-diamine in which the amino groups at positions 2 and 4 are substituted by 4-cyanophenyl and 4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl groups respectively. Used for treatment of HIV. | | Brand name | Edurant | | Clinical Use | Non-nucleoside reverse transcriptase inhibitor:
Treatment of progressive or advanced HIV infection
in combination with at least two other antivirals | | Drug interactions | Potentially hazardous interactions with other drugs
Antibacterials: avoid with clarithromycin and
erythromycin - concentration possibly increased;
concentration decreased by rifampicin and rifabutin
- avoid with rifampicin, increase dose of rilpivirine
to 50 mg daily.
Antidepressants: concentration possibly reduced by
St John’s wort - avoid.
Antiepileptics: concentration possibly reduced
by carbamazepine, fosphenytoin, oxcarbazepine,
phenobarbital, primidone and phenytoin - avoid.
Corticosteroids: avoid with dexamethasone (except
as a single dose).
Orlistat: absorption possibly reduced by orlistat.
Ulcer-healing drugs: concentration possibly reduced
by esomeprazole, lansoprazole, omeprazole,
pantoprazole and rabeprazole - avoid; avoid
histamine H2
-antagonists for 12 hours before and 4
hours after rilpiverine. | | Metabolism | Primarily undergoes oxidative metabolism mediated by
the cytochrome P450 (CYP) 3A system.
85% excreted via the faeces (25% as unchanged drug) and
6% via the urine. | | references | [1] moss d m, liptrott n j, curley p, et al. rilpivirine inhibits drug transporters abcb1, slc22a1, and slc22a2 in vitro. antimicrobial agents and chemotherapy, 2013, 57(11): 5612-5618.[2] garvey l, winston a. rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. 2009.[3] weiss j, haefeli w e. potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. international journal of antimicrobial agents, 2013, 41(5): 484-487.[4] baert l, van’t klooster g, dries w, et al. development of a long-acting injectable formulation with nanoparticles of rilpivirine (tmc278) for hiv treatment. european journal of pharmaceutics and biopharmaceutics, 2009, 72(3): 502-508. |
| 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile Preparation Products And Raw materials |
|
![4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile](/img/500287-72-9.jpg "4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile")
日本语
한국어
Français
Deutsch
España
Türkiye